>I was addressing two different points. Sorry if I wasn't clear. In any case it doesn't matter if resistance arises as a result of selection of pre-existing virus or mutation. In the first case (selection) development of resistance should be relatively rapid. In the second case (mutation) there's no reason to suspect that a mutation in CCR5 would be less likely to occur than a mutation in RT.<
It does matter which of the two resistance mechanisms we are talking about, IMO.
If the preferential-selection mechanism were as troublesome as you suggest, Selzentra would presumably afford no clinical benefit for any significant duration. Yet the drug was just approved, so clearly there’s a disconnect here.
Regarding your comment about the rate of host mutations to the CCR5 receptor, I’d like to see a citation to back up your assertion. Regards, Dew
News 
Market Data 
Discover 
